

# INDEX

## A

advertising, 11–12  
agreements  
    license, 164  
    with third-party providers, 146  
    types of, 140–141  
ANAQUA (software), 143  
anticipated profits, 23  
apportionment products, 151  
appraisals, 83  
arm's length pricing, 122  
assets  
    intangible, 4–5, 26, 95–99  
    intellectual property, 139–140  
    tangible versus intangible, 5, 26  
assignment agreements, 140  
AT&T, 95–96  
audit, intellectual property, 14,  
    128–134, 136–147  
    definition of, 130  
    information checklist, 144–147  
    overview of necessary steps,  
        138–141  
    reason for, 130–131  
    results, 131–132  
    timing of, 136–138  
audit, royalty, 126

## B

*Bard Peripheral Vascular, Inc. v.*  
    *W.L. Gore, Inc.*, 175, 181  
Bayes, Thomas, 72

Bayesian analysis, 72–75  
benchmarks and milestones,  
    underreporting of, 123  
beta, 36  
biotechnology royalty rates, 237  
Black, Fischer, 76  
Black-Scholes option pricing model,  
    76–77, 78  
*Bose Corp. v. JBL, Inc.*, 151, 154  
brands, and advertising dollars,  
    11–12  
build-up method, 36, 41–42  
business-level needs, 134

## C

call, 76  
Capital Asset Pricing Model  
    (CAPM), 36–39  
cash flow, discounted, 48  
celebrity  
    estate of, 91, 92, 93  
    image, 91  
    persona, 81–88, 93–94  
cell phone, as example of diverse  
    proprietary technologies, 6  
Chisum, Donald, 151  
Coca-Cola, 14–15  
collateral sales, 149–150  
commercial exploitation, 83–84  
    of celebrity image, 91  
    commercial relationship, 167  
commercial success, 169

comparables, 22  
compensation, full, 116  
complementary products, 151  
confidential information, 141  
consequence nodes, 58, 59  
continually evolving patent damages, 175  
convoys sales, 23–24, 149–150, 153  
    and forward-thinking royalty rate, 168  
Copyright Act of 1790, 88  
Copyright Act (Section 107), 89, 91–92  
copyrights, 88–90, 140  
    defined, 12  
    licensing, 16  
    sample royalty rates, 221–236  
*Cornell University v. Hewlett-Packard Co.*, 155–158  
corporate value  
    80% intellectual property and intangible assets, 3, 4–5, 26, 95, 128  
    management of intellectual property as business strategy, 129  
cost approach, 52

## D

damages, 27–29, 161  
*Daubert v. Merrell Dow Pharmaceuticals*, 189  
Decipher (software), 142–143  
decision analysis, 55–56  
    and Bayesian analysis, 73  
decision trees, 55–56, 57, 64, 65  
    and Bayesian analysis, 72–73  
    components and conventions, 56–63

decomposition, 56  
*Deere & Co. v. Int'l Harvester Co.*, 168, 173  
deficiency issues, 131  
descendible rights, 94  
design and development agreements, 141  
Digital Information Communications and Electronics (DICE) companies  
    and licensing, 17, 18, 19  
disallowed deductions, 124–125  
discount rate, 32–33, 48, 50, 52, 76  
discounted cash flow (DCF) method, 75–76  
distribution/distributorship agreements, 141  
docketing, 133  
document checklist, 139  
drugs  
    inventions, 8–9  
    probability of success, 46–48  
duration of protection, 22, 23, 168

## E

early-stage technology, 24  
*eBay Inc. v. MercExchange LLC*, 29, 30, 161–162, 178, 179  
economic downturn, and patent value, 95–99  
electronic reports, value of, 120  
employment and contractor agreements, 140–141  
enforcement, 6  
entire market value (EMV) rule, 28, 149–159  
    applicability issues, 155–156  
    relevant cases, 159  
equity capital, cost of, 36  
established royalty, qualifying, 185

estate, celebrity's, 91, 92, 93  
 event-driven IP audit, 137–138  
 exclusivity, 21, 165–166  
 expected cash flow approach, 34–36,  
 49–50, 75–76  
 expected inflation, 33, 34

## F

fair use, 89–90  
 Federal Rules of Evidence, 164  
 fees, license, 109–111, 112–113  
 flexibility, and option pricing  
 models, 75–78  
*Fonar Corp. v. General Electric  
 Co.*, 156  
 orward-thinking analysis, 165  
 franchise agreements, 141  
 future damages, 163–174  
 future lost profits, 174

## G

General Motors, 11  
 general-purpose IP audit, 136–137  
*Georgia-Pacific Corp. v. U.S.  
 Plywood-Champion Papers,  
 Inc.*, 28, 152–153, 154, 163,  
 166–167, 173, 174, 180  
 post-verdict royalty rate,  
 180–181  
 royalty rate, definition,  
 184–185  
 Google, and copyright law, 89–90

## H

*Hanson v. Alpine Valley Ski Area,  
 Inc.*, 164  
 Hewlett-Packard Company, 95–96  
*Cornell University v. Hewlett-  
 Packard Co.*, 155–158  
 hypothetical negotiation, 174

## I

Illinois Trade Secrets Act, 13  
 image exploitation, 86–87, 91  
 income approach, 32–34, 49, 52  
 industrial companies, and licensing,  
 18, 19  
 inflation, 33, 34  
 infringement issues, 131  
   damages, new measure of,  
   161–174  
   and forward-thinking analysis, 171  
 injunction, 161–162  
 injunctive relief, 178  
 instruction reorder buffer (IRB),  
 156–157  
 intangible assets, 4–5, 26  
 and volatility, 95–99  
 intangible properties, privacy and  
 publicity, 83  
 intellectual property  
   as 80% of corporate value, 3, 4–5,  
   26, 95, 128  
   assets, 139–140  
   audit and management, 127–147  
   audit information checklist,  
   144–147  
   and celebrity personae, 81–94  
   commercialization of, 4  
   growth in, 25–26  
   inattention as risk, 116  
   licensing, 101–174  
   and option pricing models, 77–78  
   as strategic issue, 129  
   and volatility, 95–99  
 Internal Revenue Service (IRS), 15  
 international laws, variations in, 86,  
 90  
 International Trademark Association  
 (INTA), 90  
 inventions, patented, 26

infringement, extent of use, 170–171  
 inventory issues, 131  
 investment rates of return, 33

**J**

Johnson & Johnson, 12  
 joint ventures, 101  
     agreements, 141  
 juries, 27  
 jurisdictions, 27  
     variability in, 94

**K**

*Kalman v. Berlyn Corp.*, 156

**L**

Lanham Act, 87  
     proposed amendment, 90  
 later-stage technology, 24  
 legal disputes, use of royalty rates,  
     103–104  
 Library of Congress, 12  
 license  
     questionable interpretation of,  
       125–126  
     term of, and shortened patent life,  
       168–169  
 licensing, 15–24  
     agreement, wording of, 121,  
       122, 123  
     as core strategy, 4  
     fees, 109–111, 112–113, 114  
     history of, impaired by  
       infringement, 164  
     valuation, 101  
     licensing agreements, 140, 164  
 Licensing Executive Society  
 (LES), 190  
 licensor-licensee relationship,  
     116–118, 123

    and future, 167  
     limited-purpose focused audit, 138  
     litigation venue, 27  
     Long Term Capital Management,  
       54, 80  
     lost profits, 29, 174  
     *Lucent Technologies, Inc. v.*  
       *Gateway, Inc.*, 154, 155  
     lump sum royalty, 155

**M**

Malkiel, Burton G., 67  
 management of intellectual property,  
     132–134  
     benefits of comprehensive system,  
       135–136  
     as business strategy, 128–130  
     new paradigm, 134  
     software solutions, 141–143  
     strategy, implementation,  
       audit information checklist,  
       144–147  
 mark. *See* trademarks  
 market approach, 52  
 marketing agreements, 141  
 marketplace confusion, 87  
 Markov, Andrei A., 66  
 Markov chains, 66–70  
 math errors, 119–120  
 medical device industry  
     license fees, 112–113  
     royalty rates, 111–112  
 Medtronic, Inc., 95–96, 97  
 Meriwether, John, 54  
 Merton, Robert C., 54  
 method patents, 29  
 misreported royalties, 115–126  
 monopoly, 166–167  
 Monroe, Marilyn, 93  
 Monte Carlo techniques, 63–66

Morgenstern, Oskar, 55  
Mullins, David, 54

## N

negotiations, 172–174  
net present value (NPV) method,  
75, 76  
“new” intellectual properties, 83  
New Restatement of the Law Third,  
Unfair Competition, 13  
Nike, Inc., 95–96, 97  
nonpracticing patent holders,  
29–30, 31

## O

Ocean Tomo, 4, 26, 128  
option pricing models, 75–78  
outcome nodes, 58  
ownership issues, 131

## P

*Paice LLC v. Toyota Motor Corp.*,  
175–180  
decision, 181  
*Panduit Corp. v. Stahlin Bros. Fibre  
Works, Inc.*, 164  
*Paper Converting Machine Co. v.  
Magna-Graphics Corp.*, 156  
patent infringement damages, 27–29  
patent owner distribution, 7–8  
patent protection, 9  
Patent Reform Act of 2007, 25  
patent troll, 162  
patent value, and economic  
downturn, 95–99  
patented inventions, 26  
patented technology  
increase in, 3  
optimization/loss, 181–184  
utility of, 169–170

patents, 139, 145  
increase in, 3, 4, 8–9  
terms of, 6, 168–169  
pay-as-you-go, 101  
Pepsi, 14–15  
per unit royalties, 107–108, 114  
percentage royalties, 108–109, 114  
permanent injunction, 161, 162  
persona, celebrity  
as intellectual property, 81–88,  
93–94  
multiple elements of, 94  
as private property, 85  
pharmaceutical and biotechnology  
industries  
drugs, probability of success,  
46–48  
and licensing, 17, 18, 19  
medical device industry  
license fees, 112–113  
royalty rates, 111–112, 237–260  
photography, 91–93  
Postrel, Virginia, 79–80  
post-verdict royalty rates, 176–181  
predictability, 80  
present value calculations, 34  
prestige, 170  
price erosion, 161  
price fluctuation, and royalties, 108  
privacy, right to, 84–85  
probability, 54  
and Bayesian analysis, 72–75  
Markov chains, 66–70  
probability of success, 45–49  
Procter & Gamble, 11–12, 95–96  
“Product Keys,” 190–191  
profitability, 169  
profits, future lost, 174  
protection, 21  
public domain, 14

publicity, right of, 85–87  
 put, 76

## R

random walk theory, 67

rate of return

- build-up method, 41–42
- capital asset pricing model, 36–39
- investment, 33
- required, 33–36
- venture capital rate, 42–45

rational decision making, limitations on, 78–79

reasonable exploitations, 86–87

reasonable royalty, 152, 154, 163  
 defined, 28

relief from royalty valuation, 97

reporting errors, 118–126

required rates of return, 33–36

*ResQNet.com, Inc., v. Lansa, Inc.*, 176, 186, 187

right of publicity, 85–87, 91, 93  
 ownership of, 94

right to privacy, 84–85

rights issues, 131

risk

- aversion, 79
- premium, 33–34, 36, 38–39, 41, 50
- reduction, 22, 24
- systemic, 34
- versus uncertainty, 53–54, 55–63

risk-free rate of return, 34

*Rit-Hite Corporation v. Kelley Company, Inc.*, 151, 153, 154, 156

royalty agreements, 141

royalty audits, 126

royalty base, 28–29, 150–152, 154, 157, 158

and transfer errors, 122

royalty misreporting, 115–126

disallowed deductions, 124–125

math errors, 119–120

questionable license interpretation, 125–126

rate errors, 120–122

transfer price error, 122

unreported benchmarks and milestones, 123

unreported sales, 124

unreported sublicenses, 125

royalty rates, 101, 103, 104–109, 111–112, 114, 150–152

comparable, 165

determined by, 189

distribution across industries, 106–107

for future damages, 163–174

key factors impacting, 20–24

misapplication of, 120–122

for pharmaceutical and biotechnology industries, 237–260

profitability as basis, 108–109

sales percentage, 237

sample, 193–220

standard, 185

for telecommunications industries, 261–295

trademarks and copyrights, sample, 221–236

wording of legal agreement, 121, 122, 123

*Royalty Rates for Technology*, 104–105

*Rude v. Westcott*, 164, 186

running royalty, 155

**S**

sales, unreported, 124  
 Scholes, Myron, 54, 76  
 sensitivity analysis, 61–62  
 servicemarks, 10  
 settlement agreements, 141  
 settlement licenses  
   agreements, exclusion, 185  
   comparability, 188  
 Severinsky, Alex, 176  
 shadow pricing, 70–72  
 shared directories, 133–134  
 six-year rule, 29  
 software tools  
   business-oriented, 142–143  
   legal/docketing, 142  
 spreadsheets, 133  
 stand-alone databases, 134  
*State Indus., Inc. v. Mor-Flo Indus., Inc.*, 156, 158  
 state laws, variations in, 85, 90  
 strategic issues, 131  
 sublicenses, 123, 125  
 success  
   commercial, 22  
   and forward-thinking analysis, 169  
   probability of, 45–49  
 sue-or-settle decision, 58–59  
 Supreme Court rulings, 29–31  
*Susan Maxwell v. J. Baker, Inc.*, 164  
 systemic risk, 34

**T**

tangible versus intangible assets,  
   5, 26  
 technology  
   commercialization of, 6  
   and forward-thinking analysis,  
   169–170  
   license fees, 109–111, 112–114

licensing, 16, 17  
   patent classifications, 8–9  
   royalty rates, 103–109,  
   111–112, 114  
 telecommunications industries,  
   261–295  
 telecommunications royalty rates, 261  
 territory restriction, 22  
 third-party pricing, 122  
 third-party providers, 145  
 threat of injunction, 29–30, 31  
 Toyota Motor Corp., 176–179  
   Infringement action, 176  
 trade secrets, 12–15, 139–140  
 trademark rights, and a person's  
   persona, 87  
 trademarks, 10–12, 140  
   applications, numbers of, 11  
   licensing, 16  
   Markov chains and researching  
     brand loyalty, 67–69  
     sample royalty rates, 221–236  
 transfer prices, 122  
 trend analysis, 122  
 25 percent rule, 189–191

**U**

uncertainty nodes, 58, 59, 61  
 uncertainty versus risk, 53–54, 55–63  
 underreported royalties, 116–119  
 Uniform Trade Secrets Act, 13  
*Uniloc USA v. Microsoft Corporation*, 189–191  
 university/government entities, 162  
   and licensing, 18, 19  
   and royalty misreporting, 123  
 unlawful use, 87  
 unreported sales, 124  
 up-front license fees, 109–111,  
   112–113

306 Index

U.S. Congress, 25–29  
U.S. Patent and Trademark Office  
(USPTO), 6  
U.S. Treasury securities, 34  
use of patented invention, extent of,  
170–171  
utility, 21

**V**

valuation, 1, 32–33, 34–36  
as basis for decision making,  
55–56  
of celebrity persona, 81–82, 83–84  
and economic conditions, 95–99  
and flexibility, 75–76

venture capital model, 45, 46  
venture capital rates of return,  
43–44  
venue, 27  
Verizon Communications, 12  
von Neumann, John, 55

**W**

weighted average cost of capital  
(WACOC), 36  
*Wendt v. Host Int'l, Inc.*,  
86–87  
*White v. Samsun Elec. Am., Inc.*,  
86–87  
willful infringement, 161

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>

<http://www.pbookshop.com>